{"schema_version":"secwatch.filing_event.v1","accession":"0000313143-23-000048","form_type":"8-K","ticker":"HAE","cik":"0000313143","company_name":"HAEMONETICS CORP","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.614528+00:00","generated_at":"2026-06-10T02:57:10.145841+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Haemonetics to acquire OpSens for CAD $2.90/share in cash, expected close by March 31, 2024","bullets":["Haemonetics (HAE) will pay CAD $2.90 per share for all OpSens common shares via a plan of arrangement under Québec law.","Closing conditions include 2/3 shareholder vote, HSR and Investment Canada approvals, court order, and no material adverse effect.","OpSens directors and officers owning ~4.75% of shares have agreed to vote in favor via voting agreements.","If OpSens terminates for a superior proposal or changes recommendation, it pays Haemonetics a CAD $12.075M termination fee.","The transaction must close by March 31, 2024, with an automatic 75-day extension if regulatory approvals are not yet obtained."],"urls":{"canonical":"https://secwatch.observer/filing/0000313143-23-000048","json":"https://secwatch.observer/filing/0000313143-23-000048.json","markdown":"https://secwatch.observer/filing/0000313143-23-000048.md","text":"https://secwatch.observer/filing/0000313143-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/0000313143-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/hae-20231010.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:57:10.145841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4834dc90d956672091d7fa4d1a5f0d5270e369a2","claim":"HAEMONETICS CORP entered into Arrangement Agreement with OpSens Inc., 9500-7704 Québec Inc. valued at CAD $2.90 (effective 2023-10-10).","evidence_excerpt":"On October 10, 2023, Haemonetics Corporation, a Massachusetts corporation (“ Haemonetics ” or the “ Company ”), OpSens Inc., a corporation existing under the Business Corporations Act (Québec) (“ OpSens ”), and 9500-7704 Québec Inc., a corporation existing under the Business Corporations Act (Québec) and a wholly owned subsidiary of Haemonetics (the “ Purchaser ” and, together with Haemonetics, the “ Purchaser Parties ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”), pursuant to which, among other things, the Purchaser has agreed to acquire all of the issued and outstanding common shares of OpSens (the “ Arrangement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/0000313143-23-000048-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"OpSens Inc., 9500-7704 Québec Inc."},{"label":"Value","value":"CAD $2.90"},{"label":"Effective","value":"2023-10-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}